Literature DB >> 3161944

Purification and functional analysis of the polymorphic variants of the C3b/C4b receptor (CR1) and comparison with H, C4b-binding protein (C4bp), and decay accelerating factor (DAF).

T Seya, V M Holers, J P Atkinson.   

Abstract

Four CR1 variants have been found in the normal population and are designated CR1-A (190,000 daltons), CR1-B (220,000 daltons), CR1-C (160,000 daltons), and CR1-D (250,000 daltons). In the present study, we first developed an improved chromatographic purification scheme for CR1 that does not employ a C3b affinity step. CR1 variants (A, B, and C) were then isolated, and their individual functional activity was assessed. Each possessed similar co-factor activity for I-mediated cleavage of C3(H2O), as well as for the inhibitory activity for fluid phase C3 convertases. These results indicate that, despite relatively large Mr differences, in the purified state these three CR1 variants have similar functional activities. The functional activity of CR1 was also compared with C4bp, H, and decay accelerating factor (DAF) in fluid phase assays designed to assess the inhibition of the C3 convertases and co-factor activity. On a molar basis, CR1 had approximately the same inhibitory activity as C4bp for the classical pathway convertase, and had the same as H for the alternative pathway convertase. These results indicate that CR1 encompasses the functional capabilities of both proteins. They also raise a number of interesting genetic and structural questions in regard to these complement regulatory proteins, because C4bp is thought to have multiple C4b binding domains, whereas H is reported to bind one C3b. DAF was an approximately fourfold better inhibitor of the alternative pathway convertase than CR1 or H, but was a fourfold less efficient inhibitor of the classical pathway convertase than CR1 or C4bp. The effective inhibitory capacity of DAF in these fluid phase assay systems suggests that the DAF substrate specificity is for the convertases. Fluid phase CR1 was twofold less efficient than H in serving as a co-factor for the first cleavage of fluid phase C3b, and hardly mediated the second cleavage. These data are in contrast to the co-factor activity of CR1 on a cell membrane, and provide additional evidence for the local environment being a critical modulator of the function of proteins that regulate the activation of C3.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3161944

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  20 in total

Review 1.  C4b-binding protein, a regulatory protein of complement.

Authors:  S R Barnum
Journal:  Immunol Res       Date:  1991       Impact factor: 2.829

2.  Human complement regulatory proteins expressed on mouse A9 cells containing a human chromosome 1.

Authors:  T Seya; M Okada; T Hara; M Matsumoto; S Miyagawa; M Oshimura
Journal:  Immunology       Date:  1991-12       Impact factor: 7.397

3.  Octamerization enables soluble CD46 receptor to neutralize measles virus in vitro and in vivo.

Authors:  D Christiansen; P Devaux; B Réveil; A Evlashev; B Horvat; J Lamy; C Rabourdin-Combe; J H Cohen; D Gerlier
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

4.  Identification of a complement receptor 1 peptide for inhibition of immune hemolysis.

Authors:  Jin Yu; Susanne Heck; Asim Debnath; Karina Yazdanbakhsh
Journal:  Biochem Biophys Res Commun       Date:  2006-12-11       Impact factor: 3.575

Review 5.  CR1 and the cell membrane proteins that bind C3 and C4. A basic and clinical review.

Authors:  J G Wilson; N A Andriopoulos; D T Fearon
Journal:  Immunol Res       Date:  1987       Impact factor: 2.829

6.  Membrane cofactor protein of complement is present on human fibroblast, epithelial, and endothelial cells.

Authors:  T McNearney; L Ballard; T Seya; J P Atkinson
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

7.  Structure/function studies of human decay-accelerating factor.

Authors:  W G Brodbeck; L Kuttner-Kondo; C Mold; M E Medof
Journal:  Immunology       Date:  2000-09       Impact factor: 7.397

8.  The polymorphism of the C3b/C4b receptor in the normal population and in patients with systemic lupus erythematosus.

Authors:  S Van Dyne; V M Holers; D M Lublin; J P Atkinson
Journal:  Clin Exp Immunol       Date:  1987-06       Impact factor: 4.330

9.  The rate of loss of CR1 from ageing erythrocytes in vivo in normal subjects and SLE patients: no correlation with structural or numerical polymorphisms.

Authors:  F Moldenhauer; M Botto; M J Walport
Journal:  Clin Exp Immunol       Date:  1988-04       Impact factor: 4.330

10.  Blocking measles virus infection with a recombinant soluble form of, or monoclonal antibodies against, membrane cofactor protein of complement (CD46).

Authors:  T Seya; M Kurita; T Hara; K Iwata; T Semba; M Hatanaka; M Matsumoto; Y Yanagi; S Ueda; S Nagasawa
Journal:  Immunology       Date:  1995-04       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.